6.73
0.55 (8.90%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Annexon, Inc. | Bullish | Bearish |
Stockmoo Score
|
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bain Capital Life Sciences Investors, Llc | 30 Jun 2024 | 8,449,208 |
| Alerce Investment Management, L.P. | 30 Jun 2024 | 7,406,024 |
| Woodline Partners Lp | 30 Jun 2024 | 4,071,677 |
| Logos Global Management Lp | 30 Jun 2024 | 3,300,000 |
| Gmt Capital Corp | 30 Jun 2024 | 2,939,945 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (HC Wainwright & Co., 345.77%) | Buy |
| Median | 23.00 (241.75%) | |
| Low | 16.00 (Needham, 137.74%) | Buy |
| Average | 23.00 (241.75%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 5.69 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 13 Aug 2024 | 30.00 (345.77%) | Buy | 5.69 |
| Needham | 13 Aug 2024 | 16.00 (137.74%) | Buy | 5.69 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CARSON WILLIAM H. | - | - | 0 | 0 |
| YEDNOCK TED | - | 5.82 | -5,500 | -32,010 |
| Aggregate Net Quantity | -5,500 | |||
| Aggregate Net Value ($) | -32,010 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 5.82 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| YEDNOCK TED | Officer | 05 Sep 2024 | Automatic sell (-) | 5,500 | 5.82 | 32,010 |
| CARSON WILLIAM H. | Director | 03 Sep 2024 | 3,200 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |